• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Kewaunee Scientific Reports Results for Second Quarter of Fiscal Year 2025

    12/11/24 4:04:00 PM ET
    $KEQU
    Medical Specialities
    Industrials
    Get the next $KEQU alert in real time by email

    STATESVILLE, N.C., Dec. 11, 2024 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ:KEQU) today announced results for its second quarter ended October 31, 2024.

    Kewaunee Scientific Corporation (PRNewsFoto/Kewaunee Scientific Corporation)

    Fiscal Year 2025 Second Quarter Results:

    Sales during the second quarter of fiscal year 2025 were $47,764,000, a decrease of 5.3% compared to sales of $50,436,000 from the prior year's second quarter. Pre-tax earnings for the quarter were $3,931,000 compared to $4,845,000 for the prior year quarter, a decrease of 18.9%. Net earnings were $3,008,000 compared to net earnings of $2,732,000 for the prior year quarter. EBITDA1 for the quarter was $4,883,000 compared to $5,662,000 for the prior year quarter. Diluted earnings per share was $1.01 compared to diluted earnings per share of $0.93 in the prior year quarter.

    The Company's order backlog was at a historically high level of $184.4 million on October 31, 2024, as compared to $146.3 million on October 31, 2023, and $155.6 million on April 30, 2024.

    Domestic Segment - Domestic sales for the quarter were $36,409,000, an increase of 6.5% from sales of $34,185,000 in the prior year quarter. Domestic segment net earnings was $4,524,000 compared to $3,054,000 in the prior year quarter. Domestic segment EBITDA was $6,838,000 compared to $5,230,000 for the prior year quarter. The increase in Domestic sales and earnings was primarily driven by higher product demand.

    International Segment - International sales for the quarter were $11,355,000, a decrease of 30.1% from sales of $16,251,000 in the prior year quarter. International segment net earnings was $356,000 compared to $525,000 in the prior year quarter. International segment EBITDA was $592,000 compared to $1,635,000 for the prior year quarter. The decline in sales is attributable to customer construction site delays in India which pushed out the timing of deliveries.

    Corporate Segment – Corporate segment pre-tax net loss was $2,444,000 for the quarter, as compared to a pre-tax net loss of $1,243,000 in the prior year quarter. Corporate segment EBITDA for the quarter was ($2,547,000) compared to corporate segment EBITDA of ($1,203,000) for the prior year quarter. The change in EBITDA was primarily driven by an increase in professional service and other fees during the quarter related to the acquisition of Nu Aire, Inc., which closed on November 1, 2024, and costs incurred related to Sarbanes-Oxley 404(b) compliance readiness.

    Total cash on hand on October 31, 2024 was $29,664,000, as compared to $25,938,000 on April 30, 2024. Working capital was $59,965,000, as compared to $52,144,000 at the end of the second quarter last year and $56,037,000 on April 30, 2024.

    The Company had short-term debt of $805,000 as of October 31, 2024, as compared to $3,099,000 on April 30, 2024. Long-term debt was $28,047,000 on October 31, 2024, as compared to $28,479,000 on April 30, 2024. The building lease from the Company's December 2021 sale-leaseback transaction accounts for $27,782,000 of the long-term debt on October 31, 2024 and $28,133,000 of the long-term debt on April 30, 2024. Long-term debt, net of the sale-leaseback transaction, was $265,000 on October 31, 2024 as compared to $346,000 on April 30, 2024. The Company's debt-to-equity ratio on October 31, 2024 was 0.59-to-1, as compared to 0.70-to-1 on April 30, 2024. The Company's debt-to-equity ratio, net of the sale-leaseback transaction, on October 31, 2024 was 0.14-to-1, as compared to 0.20-to-1 on April 30, 2024.

    "Our financial performance for the second quarter of fiscal year 2025 was strong," said Thomas D. Hull III, Kewaunee's President and Chief Executive Officer. "Domestic segment operating performance improved compared to last year's second quarter as a result of higher product demand, highlighting our continued health and advantage in the market. As discussed during the first quarter of fiscal year 2025, customer construction site delays in India on multiple projects continue to impact our ability to ship products and deliver services, leading to a decrease in sales and earnings when compared to the prior year second quarter."

    "Looking ahead, our backlog remains very healthy, demonstrating the continued vitality and investment in the markets in which Kewaunee participates and the success both Kewaunee and our channel partners continue to achieve in the marketplace. The strength of Kewaunee's backlog positions the company well to deliver another strong year for our fiscal year."

    "Additionally, on November 1, 2024, Kewaunee announced the acquisition of Nu Aire, Inc.," Hull continued. "Nu Aire is renowned for its manufacturing of robust containment solutions, such as biological safety cabinets, airflow products, and more, which serve a diverse range of industries. While not reflected in our second quarter fiscal year 2025 results, Nu Aire will be included going forward, beginning with our third quarter fiscal year 2025 results. It is worth noting the company incurred expenses related to the acquisition of $2.3 million in the current fiscal year, which are outlined in the attached exhibits."

    "The acquisition of Nu Aire presents a unique opportunity for Kewaunee to expand its capabilities, allowing the combined organization to better meet the diverse needs of end-users in laboratory furnishings and, through Nu Aire's established distribution partners, reach regions where Kewaunee has not previously had a presence. This move accelerates the Company's vision of becoming the market leader in the design and manufacturing of laboratory furniture and technical products essential for outfitting the laboratories of tomorrow."

    1 EBITDA is a non-GAAP financial measure. See the table below for a reconciliation of EBITDA and segment EBITDA to net earnings (loss), the most directly comparable GAAP measure.

     

    EBITDA, Segment EBITDA, Adjusted EBITDA, and Adjusted Segment EBITDA Reconciliation

    (Unaudited)

    ($ in thousands)

    Quarter Ended October 31, 2023



    Domestic



    International



    Corporate



    Consolidated

    Net Earnings (Loss)



    $                  3,054



    $                     525



    $                   (847)



    $                  2,732

    Add/(Less):

















    Interest Expense



    323



    35



    14



    372

    Interest Income



    —



    (205)



    (22)



    (227)

    Income Taxes



    1,232



    1,179



    (396)



    2,015

    Depreciation and Amortization



    621



    101



    48



    770

    EBITDA



    $                  5,230



    $                  1,635



    $                (1,203)



    $                  5,662



















    Quarter Ended October 31, 2024



    Domestic



    International



    Corporate



    Consolidated

    Net Earnings (Loss)



    $                  4,524



    $                     356



    $                (1,872)



    $                  3,008

    Add/(Less):

















    Interest Expense



    413



    19



    10



    442

    Interest Income



    —



    (133)



    (156)



    (289)

    Income Taxes



    1,241



    247



    (572)



    916

    Depreciation and Amortization



    660



    103



    43



    806

    EBITDA



    $                  6,838



    $                     592



    $                (2,547)



    $                  4,883

    Professional & Other Fees



    —



    —



                       1,5402



    1,540

    Adjusted EBITDA



    $                  6,838



    $                     592



    $                (1,007)



    $                  6,423



















    Year to Date October 31, 2023



    Domestic



    International



    Corporate



    Consolidated

    Net Earnings (Loss)



    $                  5,765



    $                     994



    $                (1,553)



    $                  5,206

    Add/(Less):

















    Interest Expense



    703



    71



    28



    802

    Interest Income



    —



    (418)



    (23)



    (441)

    Income Taxes



    2,145



    1,461



    (694)



    2,912

    Depreciation and Amortization



    1,195



    197



    96



    1,488

    EBITDA



    $                  9,808



    $                  2,305



    $                (2,146)



    $                  9,967



















    Year to Date October 31, 2024



    Domestic



    International



    Corporate



    Consolidated

    Net Earnings (Loss)



    $                  7,395



    $                     819



    $                (3,013)



    $                  5,201

    Add/(Less):

















    Interest Expense



    854



    40



    20



    914

    Interest Income



    —



    (307)



    (329)



    (636)

    Income Taxes



    2,005



    526



    (1,423)



    1,108

    Depreciation and Amortization



    1,322



    210



    89



    1,621

    EBITDA



    $                11,576



    $                  1,288



    $                (4,656)



    $                  8,208

    Professional & Other Fees



    —



    —



                       2,2703



    2,270

    Adjusted EBITDA



    $                11,576



    $                  1,288



    $                (2,386)



    $                10,478

    ______________________________

    2 Professional and other fees  incurred during the three months ended October 31, 2024 related to the Company's acquisition of Nu Aire, Inc. ("Nu Aire"), which closed on November 1, 2024

    3 Professional and other fees incurred during the six months ended October 31, 2024 related to the Company's acquisition of Nu Aire

     

    Adjusted Consolidated Statement of Operations Reconciliation

    (Unaudited)

    ($ in thousands, except per share amounts)



    Three Months Ended October 31,



    As Reported

    2024



    Professional

    & Other Fees



    Adjusted

    2024



    2023

    Net sales

    $      47,764



    $              —



    $       47,764



    $      50,436

    Cost of products sold

    33,812



    —



    33,812



    36,968

    Gross profit

    13,952



    —



    13,952



    13,468

    Operating expenses

    9,518



              1,2164



    8,302



    8,359

    Operating profit

    4,434



    1,216



    5,650



    5,109

    Pension expense

    —



    —



    —



    (40)

    Other (expense) income, net

    (61)



                 3245



    263



    148

    Interest expense

    (442)



    —



    (442)



    (372)

    Profit before income taxes

    3,931



    1,540



    5,471



    4,845

    Income tax expense

    916



                 3516



    1,267



    2,015

    Net earnings

    3,015



    1,189



    4,204



    2,830

    Less: Net earnings attributable to the non-controlling interest

    7



    —



    7



    98

    Net earnings attributable to Kewaunee Scientific Corporation

    $         3,008



    $         1,189



    $         4,197



    $         2,732

















    Net earnings per share attributable to Kewaunee Scientific Corporation stockholders















    Basic

    $           1.05



    $           0.41



    $           1.46



    $           0.94

    Diluted

    $           1.01



    $           0.40



    $           1.41



    $           0.93





    Six Months Ended October 31,



    As Reported

    2024



    Professional &

    Other Fees



    Adjusted

    2024



    2023

    Net sales

    $      96,157



    $              —



    $       96,157



    $    100,275

    Cost of products sold

    69,717



    —



    69,717



    74,893

    Gross profit

    26,440



    —



    26,440



    25,382

    Operating expenses

    19,431



              1,9467



    17,485



    16,465

    Operating profit

    7,009



    1,946



    8,955



    8,917

    Pension expense

    —



    —



    —



    (81)

    Other income, net

    266



                 3248



    590



    223

    Interest expense

    (914)



    —



    (914)



    (802)

    Profit before income taxes

    6,361



    2,270



    8,631



    8,257

    Income tax expense

    1,108



                 5189



    1,626



    2,912

    Net earnings

    5,253



    1,752



    7,005



    5,345

    Less: Net earnings attributable to the non-controlling interest

    52



    —



    52



    139

    Net earnings attributable to Kewaunee Scientific Corporation

    $         5,201



    $         1,752



    $         6,953



    $         5,206

















    Net earnings per share attributable to Kewaunee Scientific Corporation stockholders















    Basic

    $           1.82



    $            0.61



    $            2.43



    $           1.81

    Diluted

    $           1.75



    $            0.59



    $            2.34



    $           1.79

    ______________________________

    4 Professional fees incurred during the three months ended October 31, 2024 related to the Company's acquisition of Nu Aire

    5 Cost incurred related to the early termination of the Company's Revolving Credit Facility

    6 Estimated tax impact of professional and other fees incurred during the three months ended October 31, 2024 related to the Company's acquisition of Nu Aire

    7 Professional fees incurred during the six months ended October 31, 2024 related to the Company's acquisition of Nu Aire

    8 Cost incurred related to the early termination of the Company's Revolving Credit Facility

    9 Estimated tax impact of professional and other fees incurred during the six months ended October 31, 2024 related to the Company's acquisition of Nu Aire

    About Non-GAAP Measures 

    The Company includes non-GAAP financial measures such as adjusted net earnings and adjusted net earnings per share, in the information provided with this press release as supplemental information relating to its operating results. Adjusted net earnings represents GAAP net earnings adjusted for professional and other fees related to the acquisition of Nu Aire, Inc. and the corresponding tax impact. This financial information is not in accordance with, or an alternative for, GAAP-compliant financial information and may be different from the operating or non-GAAP financial information used by other companies. The Company believes that this presentation of adjusted net earnings and adjusted net earnings per share provides useful information to investors regarding certain additional financial and business trends relating to its financial condition and results of operations.

    EBITDA and Segment EBITDA are calculated as net earnings (loss), less interest expense and interest income, income taxes, depreciation, and amortization. Adjusted EBITDA and Adjusted Segment EBITDA are calculated as EBITDA or Segment EBITDA less the impact of the professional and other fees related to the Company's acquisition of Nu Aire, Inc., as discussed in more detail above. We believe EBITDA, Segment EBITDA, Adjusted EBITDA, and Adjusted Segment EBITDA allow management and investors to compare our performance to other companies on a consistent basis without regard to depreciation and amortization or the professional fees not related to our core business incurred during the current period, which can vary significantly between companies depending upon many factors. EBITDA, Segment EBITDA, Adjusted EBITDA, and Adjusted Segment EBITDA are not calculations based upon generally accepted accounting principles, and the method for calculating EBITDA, Segment EBITDA, Adjusted EBITDA, and Adjusted Segment EBITDA can vary among companies. The amounts included in the EBITDA, Segment EBITDA, Adjusted EBITDA, and Adjusted Segment EBITDA calculations, however, are derived from amounts included in the historical consolidated statements of operations. EBITDA, Segment EBITDA, Adjusted EBITDA, and Adjusted Segment EBITDA should not be considered as alternatives to net earnings (loss) or operating earnings (loss) as an indicator of the Company's operating performance, or as an alternative to operating cash flows as a measure of liquidity.

    About Nu Aire

    Founded in 1971 and based in Minneapolis, the Company is a leading manufacturer of equipment for a diverse range of laboratory and pharmacy environments. Nu Aire is the North American market share leader in biological safety cabinets and other airflow products and also offers a complete line of CO2 incubators, ultralow freezers, animal handling equipment, pharmacy compounding isolators, and parts and accessories. Nu Aire's equipment is required for safety and quality in every type of laboratory: life sciences research, clinical, hospital, biotech and pharmaceutical R&D, academia, food and beverage, industrial and more. Nu Aire's website is located at http://www.nuaire.com/. 

    About Kewaunee Scientific

    Founded in 1906, Kewaunee Scientific Corporation is a recognized global leader in the design, manufacture, and installation of laboratory, healthcare, and technical furniture products. The Company's products include steel and wood casework, fume hoods, adaptable modular systems, moveable workstations, stand-alone benches, biological safety cabinets, and epoxy resin work surfaces and sinks.

    The Company's corporate headquarters are located in Statesville, North Carolina. Sales offices are located in the United States, India, Saudi Arabia, and Singapore. Three manufacturing facilities are located in Statesville serving the domestic and international markets, and one manufacturing facility is located in Bangalore, India serving the local, Asian, and African markets. Kewaunee Scientific's website is located at http://www.kewaunee.com.  

    This press release contains statements that the Company believes to be "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact included in this press release, including statements regarding the Company's future financial condition, results of operations, business operations and business prospects, are forward-looking statements. Words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "predict," "believe" and similar words, expressions and variations of these words and expressions are intended to identify forward-looking statements. Such forward-looking statements are subject to known and unknown risks, uncertainties, assumptions, and other important factors that could significantly impact results or achievements expressed or implied by such forward-looking statements. Such factors, risks, uncertainties and assumptions include, but are not limited to: our ability to realize the benefits anticipated as a result of the Nu Aire acquisition; competitive and general economic conditions, including disruptions from government mandates, both domestically and internationally, as well as supplier constraints and other supply disruptions; changes in customer demands; technological changes in our operations or in our industry; dependence on customers' required delivery schedules; risks related to fluctuations in the Company's operating results from quarter to quarter; risks related to international operations, including foreign currency fluctuations; changes in the legal and regulatory environment; changes in raw materials and commodity costs; acts of terrorism, war, governmental action, and natural disasters and other Force Majeure events. The cautionary statements made pursuant to the Reform Act herein and elsewhere by us should not be construed as exhaustive. We cannot always predict what factors would cause actual results to differ materially from those indicated by the forward-looking statements. Over time, our actual results, performance, or achievements will likely differ from the anticipated results, performance or achievements that are expressed or implied by our forward-looking statements, and such difference might be significant and harmful to our stockholders' interest. Many important factors that could cause such a difference are described under the caption "Risk Factors," in Item 1A of our Annual Report on Form 10-K for the fiscal year ended April 30, 2024, which you should review carefully, and in our subsequent quarterly reports on Form 10-Q and current reports on Form 8-K. These reports are available on our investor relations website at www.kewaunee.com and on the SEC website at www.sec.gov. These forward-looking statements speak only as of the date of this document. The Company assumes no obligation, and expressly disclaims any obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise.

    Kewaunee Scientific Corporation

    Condensed Consolidated Statements of Operations

    (Unaudited)

    ($ and shares in thousands, except per share amounts)

     



    Three Months Ended

    October 31,



    Six Months Ended

    October 31,



    2024



    2023



    2024



    2023

    Net sales

    $       47,764



    $       50,436



    $       96,157



    $     100,275

    Cost of products sold

    33,812



    36,968



    69,717



    74,893

    Gross profit

    13,952



    13,468



    26,440



    25,382

    Operating expenses

    9,518



    8,359



    19,431



    16,465

    Operating profit

    4,434



    5,109



    7,009



    8,917

    Pension expense

    —



    (40)



    —



    (81)

    Other (expense) income, net

    (61)



    148



    266



    223

    Interest expense

    (442)



    (372)



    (914)



    (802)

    Profit before income taxes

    3,931



    4,845



    6,361



    8,257

    Income tax expense

    916



    2,015



    1,108



    2,912

    Net earnings

    3,015



    2,830



    5,253



    5,345

    Less: Net earnings attributable to the non-controlling interest

    7



    98



    52



    139

    Net earnings attributable to Kewaunee Scientific Corporation

    $          3,008



    $          2,732



    $          5,201



    $          5,206

















    Net earnings per share attributable to Kewaunee Scientific Corporation stockholders















    Basic

    $            1.05



    $            0.94



    $            1.82



    $            1.81

    Diluted

    $            1.01



    $            0.93



    $            1.75



    $            1.79

    Weighted average number of common shares outstanding















    Basic

    2,872



    2,903



    2,861



    2,882

    Diluted

    2,974



    2,931



    2,971



    2,908

     

    Kewaunee Scientific Corporation

    Condensed Consolidated Balance Sheets

    ($ in thousands)

     



    October 31,

    2024



    April 30, 2024



    (Unaudited)





    Assets







    Cash and cash equivalents

    $           25,963



    $           23,267

    Restricted cash

    3,701



    2,671

    Receivables, less allowances

    41,885



    45,064

    Inventories

    18,659



    20,679

    Prepaid expenses and other current assets

    6,228



    5,136

    Total Current Assets

    96,436



    96,817

    Net Property, Plant and Equipment

    16,990



    17,649

    Right of use assets

    6,941



    7,454

    Deferred income taxes

    8,305



    7,401

    Other assets

    5,806



    5,445

    Total Assets

    $         134,478



    $         134,766









    Liabilities and Stockholders' Equity







    Short-term borrowings

    $                805



    $             3,099

    Current portion of lease obligations

    2,221



    2,234

    Current portion of financing liability

    750



    713

    Accounts payable

    21,458



    23,262

    Other current liabilities

    11,237



    11,472

    Total Current Liabilities

    36,471



    40,780

    Long-term portion of lease obligations

    5,191



    5,669

    Long-term portion of financing liability

    27,032



    27,420

    Other non-current liabilities

    5,127



    4,688

    Total Liabilities

    73,821



    78,557

    Kewaunee Scientific Corporation Equity

    59,328



    54,760

    Non-controlling interest

    1,329



    1,449

    Total Stockholders' Equity

    60,657



    56,209

    Total Liabilities and Stockholders' Equity

    $         134,478



    $         134,766

     

    Contact:         

    Donald T. Gardner III



    704/871-3274

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/kewaunee-scientific-reports-results-for-second-quarter-of-fiscal-year-2025-302329479.html

    SOURCE Kewaunee Scientific Corporation

    Get the next $KEQU alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KEQU

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $KEQU
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Kewaunee Scientific Announces Amendment to Share Repurchase Program

      STATESVILLE, N.C., March 12, 2025 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ:KEQU) today announced an amendment to its existing share repurchase program. On March 12, 2025, the Board of Directors of Kewaunee Scientific Corporation (the "Company") amended its existing share repurchase program initially approved on August 31, 2023, and in effect September 1, 2023. The Board of Directors authorized the repurchase of up to an additional 100,000 shares of the Company's common stock under the existing share repurchase program, as amended (the "Program"), which does not

      3/12/25 5:08:00 PM ET
      $KEQU
      Medical Specialities
      Industrials
    • Kewaunee Scientific Reports Results for Third Quarter of Fiscal Year 2025

      STATESVILLE, N.C., March 12, 2025 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ:KEQU) today announced results for its third quarter ended January 31, 2025. Fiscal Year 2025 Third Quarter Results: Sales during the third quarter of fiscal year 2025 were $67,167,000, an increase of 43.6% compared to sales of $46,778,000 from the prior year's third quarter. Pre-tax earnings for the quarter were $1,275,000 compared to $3,515,000 for the prior year quarter, a decrease of 63.7%. Net earnings were $1,354,000 compared to net earnings of $2,521,000 for the prior year quarter.

      3/12/25 4:16:00 PM ET
      $KEQU
      Medical Specialities
      Industrials
    • Kewaunee Scientific to Report Results for Third Quarter Fiscal Year 2025

      STATESVILLE, N.C., Feb. 26, 2025 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ:KEQU) today announced that the Company plans to release its third quarter fiscal year 2025 financial results on Wednesday, March 12, 2025 after the close of trading. This information will be available on the Company's website www.kewaunee.com after the release. About Kewaunee Scientific Founded in 1906, Kewaunee Scientific Corporation is a recognized global leader in the design, manufacture, and installation of laboratory, healthcare, and technical furniture products. The Company's produc

      2/26/25 5:21:00 PM ET
      $KEQU
      Medical Specialities
      Industrials

    $KEQU
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Kewaunee Scientific Corporation

      SC 13G/A - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Subject)

      11/1/24 9:14:13 AM ET
      $KEQU
      Medical Specialities
      Industrials
    • SEC Form SC 13G/A filed by Kewaunee Scientific Corporation (Amendment)

      SC 13G/A - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Subject)

      2/9/24 11:44:29 AM ET
      $KEQU
      Medical Specialities
      Industrials
    • SEC Form SC 13G/A filed by Kewaunee Scientific Corporation (Amendment)

      SC 13G/A - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Subject)

      2/9/24 9:59:14 AM ET
      $KEQU
      Medical Specialities
      Industrials

    $KEQU
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Gehl Keith M bought $35,000 worth of shares (1,000 units at $35.00), increasing direct ownership by 6% to 18,500 units (SEC Form 4)

      4 - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Issuer)

      4/7/25 10:57:11 AM ET
      $KEQU
      Medical Specialities
      Industrials
    • Director Gehl Keith M bought $22,500 worth of shares (500 units at $45.00), increasing direct ownership by 3% to 17,500 units (SEC Form 4)

      4 - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Issuer)

      3/24/25 4:32:54 PM ET
      $KEQU
      Medical Specialities
      Industrials
    • Director Gehl Keith M bought $19,747 worth of shares (403 units at $49.00), increasing direct ownership by 2% to 17,000 units (SEC Form 4)

      4 - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Issuer)

      3/18/25 3:20:26 PM ET
      $KEQU
      Medical Specialities
      Industrials

    $KEQU
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Pyle Margaret B was granted 1,896 shares (SEC Form 4)

      4 - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Issuer)

      5/9/25 1:33:49 PM ET
      $KEQU
      Medical Specialities
      Industrials
    • Director Russell John was granted 1,896 shares, increasing direct ownership by 6% to 34,396 units (SEC Form 4)

      4 - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Issuer)

      5/9/25 10:58:43 AM ET
      $KEQU
      Medical Specialities
      Industrials
    • Director Gehl Keith M was granted 1,896 shares, increasing direct ownership by 10% to 20,396 units (SEC Form 4)

      4 - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Issuer)

      5/9/25 10:56:19 AM ET
      $KEQU
      Medical Specialities
      Industrials

    $KEQU
    Financials

    Live finance-specific insights

    See more
    • Kewaunee Scientific Reports Results for Third Quarter of Fiscal Year 2025

      STATESVILLE, N.C., March 12, 2025 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ:KEQU) today announced results for its third quarter ended January 31, 2025. Fiscal Year 2025 Third Quarter Results: Sales during the third quarter of fiscal year 2025 were $67,167,000, an increase of 43.6% compared to sales of $46,778,000 from the prior year's third quarter. Pre-tax earnings for the quarter were $1,275,000 compared to $3,515,000 for the prior year quarter, a decrease of 63.7%. Net earnings were $1,354,000 compared to net earnings of $2,521,000 for the prior year quarter.

      3/12/25 4:16:00 PM ET
      $KEQU
      Medical Specialities
      Industrials
    • Kewaunee Scientific Reports Results for Second Quarter of Fiscal Year 2025

      STATESVILLE, N.C., Dec. 11, 2024 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ:KEQU) today announced results for its second quarter ended October 31, 2024. Fiscal Year 2025 Second Quarter Results: Sales during the second quarter of fiscal year 2025 were $47,764,000, a decrease of 5.3% compared to sales of $50,436,000 from the prior year's second quarter. Pre-tax earnings for the quarter were $3,931,000 compared to $4,845,000 for the prior year quarter, a decrease of 18.9%. Net earnings were $3,008,000 compared to net earnings of $2,732,000 for the prior year quarter.

      12/11/24 4:04:00 PM ET
      $KEQU
      Medical Specialities
      Industrials

    $KEQU
    SEC Filings

    See more
    • SEC Form SD filed by Kewaunee Scientific Corporation

      SD - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Filer)

      5/9/25 10:54:08 AM ET
      $KEQU
      Medical Specialities
      Industrials
    • SEC Form 144 filed by Kewaunee Scientific Corporation

      144 - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Subject)

      3/31/25 4:23:01 PM ET
      $KEQU
      Medical Specialities
      Industrials
    • SEC Form 10-Q filed by Kewaunee Scientific Corporation

      10-Q - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Filer)

      3/14/25 10:22:53 AM ET
      $KEQU
      Medical Specialities
      Industrials